| Treatment with tiludronate has a similar effect to risedronate on Paget's disease activity assessed by bone markers and bone scintigraphy. | |
| | |
MedLine Citation:
|
PMID: 17543143 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
OBJECTIVE:To compare the effects of tiludronate and risedronate on Paget's disease activity assessed by biochemical markers of bone turnover and quantitative bone scintigraphy. METHODS: An open-labeled non-randomized study was performed in 49 patients with Paget's disease who had completed treatment with tiludronate (400 mg/d) for 3 months (28 patients) or risedronate (30 mg/d) for 2 months (21 patients). Biochemical markers of bone turnover, including serum total alkaline phosphatase (TAP), bone alkaline phosphatase (BAP), procollagen type I N propeptide (PINP) and urinary N-terminal cross-linking telopeptide of type I collagen (NTX) were measured at baseline and at 6 and 12 months after the end of treatment. Quantitative bone scintigraphy at baseline and 6 months after the end of treatment was performed in all patients obtaining a scintigraphic activity index (SAI). RESULTS: At baseline there were no significant differences in disease activity between both groups of patients, since markers of bone turnover as well as SAI were similar in both groups. The effects of tiludronate and risedronate in reducing the biochemical markers of bone turnover were comparable at 6 months (tiludronate vs risedronate: TAP -52% vs -43%; BAP -69% vs -56%; PINP -68% vs -63%; NTX -62% vs -59%) and at 12 months after the end of treatment (tiludronate vs risedronate: TAP -47% vs -36%; BAP -57% vs -46%; PINP -57% vs -52%; NTX -51% vs -52%). The effects of tiludronate and risedronate on SAI were also similar 6 months after the discontinuation of treatment. In addition, the percentage of patients who showed normalized serum TAP levels at 6 months after treatment were similar with both agents (74% with tiludronate and 70% with risedronate). CONCLUSION: Tiludronate and risedronate given at the currently recommended dosages induce similar responses in Paget's disease activity. |
| | |
Authors:
|
P Peris; L Alvarez; S Vidal; M A Martínez; A Monegal; N Guañabens |
Related Documents
:
|
16777503 - Etidronate for fracture prevention in amyotrophic lateral sclerosis: a randomized contr... 22977603 - Oxidative stress markers may not be early markers of doxorubicin-induced cardiotoxicity... 23650913 - Merits of prophylactic sclerotherapy for esophageal varices concomitant unresectable he... |
Publication Detail:
|
Type: Clinical Trial; Comparative Study; Journal Article; Research Support, Non-U.S. Gov't |
Journal Detail:
|
Title: Clinical and experimental rheumatology Volume: 25 ISSN: 0392-856X ISO Abbreviation: Clin. Exp. Rheumatol. Publication Date: 2007 Mar-Apr |
Date Detail:
|
Created Date: 2007-06-04 Completed Date: 2007-08-30 Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 8308521 Medline TA: Clin Exp Rheumatol Country: Italy |
Other Details:
|
Languages: eng Pagination: 206-10 Citation Subset: IM |
Affiliation:
|
Services of Rheumatology, Hospital Clinic, University of Barcelona, Institut d'Investigacions Biomèdiques August Pi I Sunyer (IDIBAPS), Barcelona, Spain. 22848ppb@comb.es |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Adult Aged Aged, 80 and over Alkaline Phosphatase / blood Biological Markers / blood, urine Bone Density Conservation Agents / therapeutic use* Collagen Type I / urine Creatinine / urine Diphosphonates / therapeutic use* Etidronic Acid / analogs & derivatives*, therapeutic use Female Humans Male Middle Aged Osteitis Deformans / drug therapy*, metabolism, radionuclide imaging Peptide Fragments / blood Peptides / urine Procollagen / blood Radionuclide Imaging / methods |
| Chemical | |
Reg. No./Substance:
|
0/Biological Markers; 0/Bone Density Conservation Agents; 0/Collagen Type I; 0/Diphosphonates; 0/Peptide Fragments; 0/Peptides; 0/Procollagen; 0/collagen type I trimeric cross-linked peptide; 0/procollagen Type I N-terminal peptide; 105462-24-6/risedronic acid; 2809-21-4/Etidronic Acid; 60-27-5/Creatinine; 89987-06-4/tiludronic acid; EC 3.1.3.1/Alkaline Phosphatase |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Cross-cultural adaptation, reliability and validity of the Patient Rated Elbow Evaluation (PREE) for...
Next Document: Is Taurolidine a candidate for treatment of rheumatoid arthritis?